Taysha Gene Therapies, Inc. — Balance Sheet Charts
8 snapshots of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Assets vs Liabilities
Cash Position Breakdown
Debt Structure
Working Capital Components
Capital Structure (LT Debt / Cash / Equity)
Total Assets↑+114.1% +$183M
$343M
Current Assets↑+128.4% +$183M
$325M
Cash & Equivalents↑+130.0% +$181M
$320M
Net PPE↓-10.0% -$749K
$7M
Total Liabilities↑+8.5% +$8M
$96M
Current Liabilities↑+1.2% +$325K
$27M
Account Payables↑+74.7% +$3M
$6M
Long-Term Debt↑+14.0% +$6M
$50M
Stockholders Equity↑+245.2% +$175M
$247M
Retained Earnings↓-18.1% -$109M
$-711M
Operating Lease ROU Asset↑+12.6% +$1M
$9M
Operating Lease Liability↑+13.2% +$2M
$20M
Gross PP&E↑+3.2% +$351K
$11M
Accumulated Depreciation↑+30.7% +$1M
$5M
Debt Due Y1
—
Debt Due Y2
—
Debt Due Y3↑+0.0% +$0
$19M
Debt Due Y4↓-36.0% -$7M
$12M
Debt Due Y5↑+78.6% +$17M
$38M
Total Debt Carrying Amount↑+25.0% +$10M
$50M